Female Sexual Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Female Sexual Dysfunction Pipeline Drugs Market Report Overview
Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure, and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.
The female sexual dysfunction pipeline drugs market research report provides comprehensive information on the therapeutics under development for female sexual dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for female sexual dysfunction and features dormant and discontinued projects.
Female Sexual Dysfunction Pipeline Drugs Market Segmentation by Targets
The key targets in the female sexual dysfunction pipeline drugs market are Androgen Receptor, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, D2 Dopamine Receptor, Melanocortin Receptor 4, 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, and 5-Hydroxytryptamine Receptor 2C among others. The Androgen Receptor is the leading target in the pipeline.
Female Sexual Dysfunction Pipeline Drugs Market Analysis by Targets
For more target insights into the female sexual dysfunction pipeline drugs market, download a free report sample
Female Sexual Dysfunction Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the female sexual dysfunction pipeline products market are Androgen Receptor Agonist, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Melanocortin Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 2C Antagonist, and Adenosine Receptor A3 Agonist among others. Androgen Receptor Agonist is the leading MoA in the pipeline market.
Female Sexual Dysfunction Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights into the female sexual dysfunction pipeline products market, download a free report sample
Female Sexual Dysfunction Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the female sexual dysfunction pipeline products market are oral, subcutaneous, nasal, topical, vaginal, and sublingual among others. Oral is the leading RoA.
Female Sexual Dysfunction Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights into the female sexual dysfunction pipeline products market, download a free report sample
Female Sexual Dysfunction Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the female sexual dysfunction pipeline drugs market are small molecule, synthetic peptides, cell therapy, and peptide. Small molecule is the leading molecule type.
Female Sexual Dysfunction Pipeline Drugs Market Analysis by Molecule Types
For more molecule type insights into the female sexual dysfunction pipeline drugs market, download a free report sample
Female Sexual Dysfunction Pipeline Products Market - Competitive Landscape
Some of the leading companies in the female sexual dysfunction pipeline products market are S1 Biopharma Inc, Freya Pharma Solutions BV, Jupiter Wellness Inc, Kuhnil Pharmaceutical Co Ltd, Palatin Technologies Inc, Thomas Advanced Medical LLC, Autotelic Bio Inc, and Callitas Therapeutics Inc among others. S1 Biopharma Inc is the leading company in the female sexual dysfunction pipeline products market.
Female Sexual Dysfunction Pipeline Products Market Analysis by Companies
To know more about the leading players in the female sexual dysfunction pipeline products market, download a free report sample
Female Sexual Dysfunction Pipeline Products Market Report Overview
Key Targets | Androgen Receptor, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, D2 Dopamine Receptor, Melanocortin Receptor 4, 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, and 5-Hydroxytryptamine Receptor 2C |
Key Mechanisms of Action | Androgen Receptor Agonist, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Melanocortin Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 2C Antagonist, and Adenosine Receptor A3 Agonist |
Key Routes of Administration | Oral, Subcutaneous, Nasal, Topical, Vaginal, and Sublingual |
Key Molecule Type | Small Molecule, Synthetic Peptide, Cell Therapy, and Peptide |
Leading Companies | S1 Biopharma Inc, Freya Pharma Solutions BV, Jupiter Wellness Inc, Kuhnil Pharmaceutical Co Ltd, Palatin Technologies Inc, Thomas Advanced Medical LLC, Autotelic Bio Inc, and Callitas Therapeutics Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of female sexual dysfunction.
- The pipeline guide reviews pipeline therapeutics for female sexual dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in female sexual dysfunction therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates female sexual dysfunction therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for female sexual dysfunction
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for female sexual dysfunction.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the female sexual dysfunction pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Callitas Therapeutics Inc
Can-Fite BioPharma Ltd
Dare Bioscience Inc
Endoceutics Inc
Freya Pharma Solutions BV
Jupiter Wellness Inc
Kuhnil Pharmaceutical Co Ltd
Lennham Pharmaceuticals Inc
Palatin Technologies Inc
S1 Biopharma Inc
TherapeuticsMD Inc
Thomas Advanced Medical LLC
Viramal Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the female sexual dysfunction pipeline products market?
The key targets in the female sexual dysfunction pipeline products market are Androgen Receptor, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, D2 Dopamine Receptor, Melanocortin Receptor 4, 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, and 5-Hydroxytryptamine Receptor 2C.
-
What are the key mechanisms of action in the female sexual dysfunction pipeline products market?
The key mechanisms of action in the female sexual dysfunction pipeline products market are Androgen Receptor Agonist, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Melanocortin Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 2C Antagonist, and Adenosine Receptor A3 Agonist.
-
What are the key routes of administration in the female sexual dysfunction pipeline products market?
The key routes of administration in the female sexual dysfunction pipeline products market are oral, subcutaneous, nasal, topical, vaginal, and sublingual.
-
What are the key molecule types in the female sexual dysfunction pipeline products market?
The key molecule types in the female sexual dysfunction pipeline products market are small molecule, synthetic peptide, cell therapy, and peptide.
-
Which are the leading companies in the female sexual dysfunction pipeline products market?
Some of the leading companies in the female sexual dysfunction pipeline products market are S1 Biopharma Inc, Freya Pharma Solutions BV, Jupiter Wellness Inc, Kuhnil Pharmaceutical Co Ltd, Palatin Technologies Inc, Thomas Advanced Medical LLC, Autotelic Bio Inc, and Callitas Therapeutics Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.